Urological cancers, prostate cancer, testicular cancer, bladder cancer and palliative cancers
Urology; prostate disease including prostate cancer; testicular cancer; bladder cancer; urological oncology treating with IMRT, IGRT and brachytherapy; chemotherapy including docetaxel and cabazitaxel; hormone therapy including abiraterone (Zytiga) and enzalutamide (Xtandi); bone therapy with Zometa and Denosumab.
British Medical Association
Current NHS post
Consultant Clinical Oncologist, Oxford Cancer Centre and Oxford University Hospitals NHS Trust.
Dr Philip Camilleri was appointed as Consultant Clinical Oncologist in 2006 having trained in clinical oncology in Oxford. He currently specialises in urological cancers - specifically prostate, bladder and testicular cancers - and provides chemotherapy, hormonal as well as radiotherapy treatment.
Dr Camilleri delivers prostate brachytherapy at the Oxford Cancer Centre. He also provides intensity modulated radiotherapy (IMRT) with image guidance (IGRT) for prostate cancers. He is involved in research for most urological cancers.
- MD University Of Malta 1995.
- MRCP Royal College of Physicians (London) 1999.
- FRCR Royal College of Radiologists (London) 2003.
Technical radiotherapy with stereotactic, image guided therapy as well as targeted therapy using advanced imaging techniques.
Prostate brachytherapy, image-guided radiotherapy (IGRT).